SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

作者：Rong Xu, Difei Lian, Yan Xie, Zhilei Chen, Yan Wang, Lin Mu, Yuan Wang, Baoyu Zhang · 发表于：Frontiers in Bioscience-Landmark · 年份：2023 · DOI：10.31083/j.fbl2807134 · 被引用次数：19 · 研究领域：Liver Disease Diagnosis and Treatment、Diet, Metabolism, and Disease、Natural Antidiabetic Agents Studies

Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin resistance, obesity, type 2 diabetes, and cardiovascular disease, and has become one of the main causes of chronic liver disease worldwide. At present, there is no specific drug for the treatment of NAFLD; lifestyle interventions including dietary control and exercise are recommended as routine treatments. As a drug for the treatment of type 2 diabetes, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors may also play a beneficial role in the treatment of NAFLD. This article reviews the mechanism of SGLT-2 inhibitors in the treatment of NAFLD.